Back

Impact of oral anticoagulants in frail atrial fibrillation patients: a report from an observational registry of european patients

28 August 2023 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation stroke prevention with oral anticoagulants in difficult cases Oral Anticoagulation ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Marco Proietti

University of Milan, Milan (Italy)

7 More presentations in this session

Presentation thumbnail
Anticoagulation-associated bleeding in patients randomised to screening for atrial fibrillation or usual care
Doctor E. Kongebro (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of anticoagulation for atrial fibrillation in cirrhotic patients
Doctor J. Song (Los Angeles, US)
Abstract Slides Video
Presentation thumbnail
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study
Professor R. De Caterina (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Anticoagulation therapy in patients with atrial fibrillation and active cancer
Doctor J. Jaakkola (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Individual risk prediction of anticoagulation in atrial fibrillation patients with cirrhosis
Assistant Professor I. Kim (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation stroke prevention with oral anticoagulants in difficult cases

The Event

Event poster

ESC Congress 2023

28 August 2023 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Direct oral anticoagulation versus warfarin in atrial fibrillation: a nationwide cohort study of effectiveness and safety among frail patients
thumbnail
Congress Presentation
Discussant review - FRAIL-AF
thumbnail
Congress Presentation
Effect of perceived and objectively-assessed frailty on outcomes in edoxaban-treated patients with atrial fibrillation: data from the ETNA-AF-Europe 4-year follow-up

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources